Roche Diagnostics Operations, Inc.

United States of America

Back to Profile

1-100 of 1,364 for Roche Diagnostics Operations, Inc. Sort by
Query
Aggregations
IP Type
        Patent 1,284
        Trademark 80
Jurisdiction
        United States 954
        World 406
        Canada 3
        Europe 1
Date
New (last 4 weeks) 7
2024 March (MTD) 5
2024 February 11
2024 January 16
2023 December 7
See more
IPC Class
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor 269
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system 191
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids 157
G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices 104
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers 96
See more
NICE Class
09 - Scientific and electric apparatus and instruments 40
10 - Medical apparatus and instruments 36
05 - Pharmaceutical, veterinary and sanitary products 24
01 - Chemical and biological materials for industrial, scientific and agricultural use 20
42 - Scientific, technological and industrial services, research and design 6
See more
Status
Pending 278
Registered / In Force 1,086
  1     2     3     ...     14        Next Page

1.

HIGHLY WATER-SOLUBLE AND STABLE CHEMOSENSOR FOR CYSTEINE

      
Application Number 18468249
Status Pending
Filing Date 2023-09-15
First Publication Date 2024-03-28
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Fomin, Maksim
  • Kuchelmeister, Hannes

Abstract

The present invention relates to chemical probes for the improved detection of cysteine in a test sample, preferably an aqueous test sample, as well as respective uses and kits.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms

2.

AUTOMATED ANALYSIS DEVICE, AND METHOD FOR OPERATING AUTOMATED ANALYSIS DEVICE

      
Application Number JP2023030361
Publication Number 2024/062831
Status In Force
Filing Date 2023-08-23
Publication Date 2024-03-28
Owner
  • HITACHI HIGH-TECH CORPORATION (Japan)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Onose Toma
  • Shibuya Satoshi
  • Takakura Tatsuki
  • Datz Stefan
  • Foester Elisabeth
  • Pauselius-Fuchs Ursula
  • Bishr Bassem
  • Degroot Peter

Abstract

This automated analysis device comprises an analyzing unit 40 for analyzing a sample, and a control device 20 for controlling operations of each mechanism of the analyzing unit 40, wherein the control device 20 calculates a waiting time that a user should wait until the sample or a consumable required to analyze the sample is replaced, on the basis of a time at which the sample or the consumable is to be used last, in an analysis schedule created at a time point at which a replacement request for the sample or the consumable is accepted. By this means, the present invention provides an automated analysis device, and a method for operating the automated analysis device, capable of improving work efficiency.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

3.

REAGENT FOR MASS SPECTROMETRY

      
Application Number 18500149
Status Pending
Filing Date 2023-11-02
First Publication Date 2024-03-21
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Heindl, Dieter
  • Josel, Hans-Peter
  • Kobold, Uwe
  • Seidel, Christoph
  • Rempt, Martin
  • Leinenbach, Andreas
  • Prencipe, Giuseppe
  • Baecher, Silvia
  • Loibl, Simon Ferdinand
  • Geiermann, Anna-Skrollan
  • Milic, Jelena
  • Pirkl, Nicole

Abstract

The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.

IPC Classes  ?

  • C07D 249/06 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
  • C07D 203/04 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
  • C07D 249/04 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
  • C07D 257/04 - Five-membered rings
  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 471/04 - Ortho-condensed systems

4.

MEDICAL LABORATORY COMPUTER SYSTEM

      
Application Number 18463834
Status Pending
Filing Date 2023-09-08
First Publication Date 2024-03-21
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Preuss-Dodhy, Asad

Abstract

A healthcare computer system, the computer system comprising a communications module, a string generation module, a one-way function module and an anonymised data generation module. The communications module is configured to receive one or more healthcare data packets, each healthcare data packet including: data pertaining to one or more medical analytical tests performed on a sample; a sample identifier, identifying the sample; and a timestamp, indicating when the analytical test(s) was performed. The string generation module is configured to generate a string based on the sample identifier and the timestamp. The one-way function module is configured to apply a one-way function to the generated string to generate an anonymised sample identifier. The anonymised data generation module is configured to generate an anonymised healthcare data packet including the data pertaining to the one or more medical analytical tests and the anonymised sample identifier.

IPC Classes  ?

  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G06F 21/60 - Protecting data
  • G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
  • H04L 9/40 - Network security protocols

5.

HEALTHCARE DATA PROCESSING CAPACITY MANAGEMENT

      
Application Number 18457388
Status Pending
Filing Date 2023-08-29
First Publication Date 2024-03-07
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Lira Rueda, Javier

Abstract

A healthcare data management system for managing processing capacity in a healthcare data management system. The healthcare data management system includes: one or more processing pipelines connected to one or more of the medical devices and configured to receive medical data therefrom, wherein each processing pipeline comprises a plurality of processing stages arranged in series and configured to perform respective operations on the received healthcare data, wherein each processing stage is implemented on a stateless atomic processing unit; a healthcare middleware is configured to receive processed data therefrom and to provide the processed data to a healthcare information management system; a performance management unit is configured to monitor a performance of the or each processing pipeline and adjust a number of stateless atomic processing units implementing a given processing stage within a given processing pipeline based on the monitored performance.

IPC Classes  ?

  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G06F 9/48 - Program initiating; Program switching, e.g. by interrupt
  • G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms

6.

MONITORING DEVICE FOR MONITORING A SAMPLE HANDLING SYSTEM

      
Application Number 18502331
Status Pending
Filing Date 2023-11-06
First Publication Date 2024-02-29
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Mehta, Kumar Roshan

Abstract

A monitoring device for monitoring a sample handling system comprising: a sliding unit comprising a sliding surface, wherein the sliding unit is configured for sliding over a sample transport device of the sample handling system; and an imaging streaming unit comprising s camera, wherein the camera is configured for capturing a plurality of images, wherein the imaging streaming unit comprises an imaging communication interface for providing the plurality of captured images to a transport control system of the sample handling system. A monitoring device for monitoring a sample handling system comprising: a sliding unit comprising a sliding surface, wherein the sliding unit is configured for sliding over a sample transport device of the sample handling system; and an imaging streaming unit comprising s camera, wherein the camera is configured for capturing a plurality of images, wherein the imaging streaming unit comprises an imaging communication interface for providing the plurality of captured images to a transport control system of the sample handling system. Further disclosed is a transport control system for controlling transport of a plurality of sample container holders of a sample handling system, a sample handling system for handling a plurality of samples, a method for identifying an obstacle, a method for determining a distance between the obstacle and a monitoring device and a method for controlling a monitoring device and computer programs and computer-readable storage media for performing the methods.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
  • G06T 7/55 - Depth or shape recovery from multiple images
  • G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
  • G06V 20/64 - Three-dimensional objects

7.

AUTOMATED VALIDATION OF MEDICAL DATA

      
Application Number 17896165
Status Pending
Filing Date 2022-08-26
First Publication Date 2024-02-29
Owner
  • Roche Diagnostics Operations, Inc. (USA)
  • Qilu Hospital of Shandong University (China)
Inventor
  • Liu, Daquan
  • Qian, Yin
  • Tao, Xiaojun
  • Wang, Hongchun
  • Xing, Weibin
  • Zhang, Chenxi
  • Zhang, Yi
  • Zhou, Qi

Abstract

Embodiments of the present disclosure relate to automated validation of medical data. Some embodiments of the present disclosure provide a method for medical data validation. The method comprises obtaining target medical data generated in a medical test and obtaining a machine learning model for validating medical data. The machine learning model represents an association between the medical data and validation results, the validation results indicating information about predetermined actions to be performed on the medical data. The method further comprises determining a target validation result for the target medical data by applying the target medical data to the machine learning model, the target validation result indicating information about a target action selected from the predetermined actions to be performed on the target medical data. Through the solution, it is possible to achieve automated medical data validation with high accuracy and efficiency as well as reduced manual efforts.

IPC Classes  ?

  • G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
  • G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

8.

TRANSGLUTAMINASE SUBSTRATES FOR LABELING

      
Application Number 18506022
Status Pending
Filing Date 2023-11-09
First Publication Date 2024-02-22
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Benz, Juliane
  • Jochum, Simon
  • Hemann, Matthias

Abstract

Fusion polypeptides are disclosed which are substrates for Kutzneria albida transglutaminase. The fusion polypeptides comprise one or more FKBP chaperone(s) and a target polypeptide. Each of these elements is separated from the neighboring element by a linker amino acid sequence. It was found that inserting glutamic acid containing transglutaminase recognition motifs into the linker amino acid chains is advantageous. Subsequent labeling reactions catalyzed by the transglutaminase surprisingly provide labeled fusion polypeptides have superior properties when compared with chemically random-labeled fusion polypeptides of similar design. Assays and kits are provided for in vitro detection of target antibodies in samples.

IPC Classes  ?

  • C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

9.

Bottle

      
Application Number 29816569
Grant Number D1015160
Status In Force
Filing Date 2021-11-23
First Publication Date 2024-02-20
Grant Date 2024-02-20
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Weymann, Alex

10.

Bottle

      
Application Number 29816591
Grant Number D1014271
Status In Force
Filing Date 2021-11-23
First Publication Date 2024-02-13
Grant Date 2024-02-13
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Weymann, Alex

11.

Bottle

      
Application Number 29816593
Grant Number D1014272
Status In Force
Filing Date 2021-11-23
First Publication Date 2024-02-13
Grant Date 2024-02-13
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Weymann, Alex

12.

Bottle

      
Application Number 29816571
Grant Number D1014270
Status In Force
Filing Date 2021-11-23
First Publication Date 2024-02-13
Grant Date 2024-02-13
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Weymann, Alex

13.

Bottle

      
Application Number 29816594
Grant Number D1014273
Status In Force
Filing Date 2021-11-23
First Publication Date 2024-02-13
Grant Date 2024-02-13
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Weymann, Alex

14.

Bottle

      
Application Number 29816596
Grant Number D1014274
Status In Force
Filing Date 2021-11-23
First Publication Date 2024-02-13
Grant Date 2024-02-13
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Weymann, Alex

15.

BRANCHED-CHAIN AMINES IN ELECTROCHEMILUMINESCENCE DETECTION

      
Application Number 17405742
Status Pending
Filing Date 2021-08-18
First Publication Date 2024-02-08
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Josel, Hans-Peter
  • Andres, Herbert
  • Windfuhr, Michaela
  • Larbolette, Oliver
  • Quint, Stefan

Abstract

The disclosure concerns methods for the detection of an analyte in a sample by electro-chemiluminescence using new reagent compositions. New reagent compositions, reagent kits for measuring electrochemiluminscence (ECL) and electrochemiluminescence detection methods using the new reagent compositions are disclosed. In particular, the disclosure relates to the use of novel combinations of compounds which can be used in said measurements to provide improved assay performance.

IPC Classes  ?

  • G01N 21/76 - Chemiluminescence; Bioluminescence
  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
  • G01N 21/66 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence

16.

Bottle

      
Application Number 29816574
Grant Number D1013527
Status In Force
Filing Date 2021-11-23
First Publication Date 2024-02-06
Grant Date 2024-02-06
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Weymann, Alex

17.

Bottle

      
Application Number 29816576
Grant Number D1013528
Status In Force
Filing Date 2021-11-23
First Publication Date 2024-02-06
Grant Date 2024-02-06
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Weymann, Alex

18.

SAMPLE VESSEL CLOSURE METHOD, MOVABLE CAP GRIPPER AND SAMPLE VESSEL CLOSURE SYSTEM FOR AUTOMATICALLY CLOSING AN OPEN END OF A SAMPLE VESSEL WITH A CLOSURE CAP

      
Application Number 18353485
Status Pending
Filing Date 2023-07-17
First Publication Date 2024-02-01
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Kees, Marius

Abstract

A method for automatically closing an open end of a sample vessel with a closure cap, including, inter alia, the steps of grasping an upper part of the closure cap at its outer circumference by means of a cap gripper with at least two gripper fingers comprising respective top thrust ledges extending at least in part over a recess provided by a lateral gripping face, and of pushing the closure cap into the open end of the sample vessel by means of the top thrust ledge. In addition, a respective movable cap gripper for automatically closing the open end of the sample vessel with the closure cap as well as a respective sample vessel closure system is provided.

IPC Classes  ?

  • B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

19.

LEUKOTRIENE A4 HYDROLASE (LTA4H) AS (BLOOD) BIOMARKER FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME

      
Application Number EP2023070091
Publication Number 2024/017982
Status In Force
Filing Date 2023-07-20
Publication Date 2024-01-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Martin, Klammer
  • Sillman, Johanna Carolina
  • Mang, Anika
  • Hund, Martin
  • Di Domenico, Annunziata
  • Allegranza, Deirdre Mary

Abstract

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Leukotriene A4 Hydrolase (LTA4H) in a sample of the subject.

IPC Classes  ?

  • G01N 33/88 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins

20.

METEORIN-LIKE PROTEIN (METRNL) AS (BLOOD) BIOMARKER FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME

      
Application Number EP2023070092
Publication Number 2024/017983
Status In Force
Filing Date 2023-07-20
Publication Date 2024-01-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Hund, Martin
  • Mang, Anika
  • Martin, Klammer
  • Allegranza, Deirdre Mary
  • Di Domenico, Annunziata
  • Sillman, Johanna Carolina

Abstract

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Meteorin-like protein (METRNL) in a sample of the subject.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

21.

FIBROBLAST GROWTH FACTOR BINDING PROTEIN 1 (FGFBP1) AS (BLOOD) BIOMARKER FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME

      
Application Number EP2023070094
Publication Number 2024/017985
Status In Force
Filing Date 2023-07-20
Publication Date 2024-01-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Allegranza, Deirdre Mary
  • Di Domenico, Annunziata
  • Hund, Martin
  • Martin, Klammer
  • Mang, Anika
  • Sillman, Johanna Carolina

Abstract

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Fibroblast Growth Factor-Binding Protein 1 (FGFBP1) in a sample of the subject.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

22.

PROCESSING OF TEST SAMPLES IN A LABORATORY SETTING

      
Application Number 18335513
Status Pending
Filing Date 2023-06-15
First Publication Date 2024-01-25
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Suárez Novau, Luis

Abstract

A computer-implemented method of automatically locating and processing test sample(s) from a patient within a laboratory setting 100 is disclosed. The method comprises determining that a test sample has not been processed by any device in the laboratory and the test sample is still within a time period of processing, performing inquiry of historical data of previous non-located test samples maintained in a database for possible locations of non-located test sample, and notifying laboratory operator of a location with a highest probability of test sample location based on the historical data.

IPC Classes  ?

  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis

23.

CONSOLIDATION AND PRIORITIZATION OF PATIENT CRITICAL NOTIFICATIONS

      
Application Number 18356856
Status Pending
Filing Date 2023-07-21
First Publication Date 2024-01-25
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • De Magalhaes, Chloe
  • Ibrahim, Yasser Mohamed Reda Abdelgawad
  • Pérez Pérez, José Carlos

Abstract

A computer-implemented method of consolidating critical information for a patient in a laboratory is presented. The method comprises selecting a patient to monitor from a population of patients associated with the laboratory, extracting information for the patient from a plurality of laboratory sources in the laboratory, determining if the extracted patient information is critical to care of the patient, and outputting the extracted patient critical information to a single display dashboard for display to a laboratory operator.

IPC Classes  ?

  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
  • G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms

24.

PSP94 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS

      
Application Number 18478291
Status Pending
Filing Date 2023-09-29
First Publication Date 2024-01-25
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Flohr, Aljoscha Michael
  • Georgopoulou, Aikaterini
  • Hund, Martin
  • Klammer, Martin

Abstract

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis and in particular early stages to methods of selecting a patient for therapy and to methods for monitoring disease progression in a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of PSP94 in a sample of the patient, and comparing the determined amount or concentration to a reference.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

25.

RATIO BETWEEN LTA4H AND METRNL IN THE ASSESSMENT OF POLYCYSTIC OVARIAN SYNDROME

      
Application Number EP2023070093
Publication Number 2024/017984
Status In Force
Filing Date 2023-07-20
Publication Date 2024-01-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Allegranza, Deirdre Mary
  • Di Domenico, Annunziata
  • Hund, Martin
  • Martin, Klammer
  • Mang, Anika
  • Sillman, Johanna Carolina

Abstract

The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total LTA4H in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentration determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.

IPC Classes  ?

  • G01N 33/88 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins

26.

RATIO BETWEEN FGFBP1 AND METRNL IN THE ASSESSMENT OF POLYCYSTIC OVARIAN SYNDROME

      
Application Number EP2023070111
Publication Number 2024/017988
Status In Force
Filing Date 2023-07-20
Publication Date 2024-01-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Martin, Klammer
  • Mang, Anika
  • Allegranza, Deirdre
  • Di Domenico, Annunziata
  • Hund, Martin
  • Sillman, Johanna

Abstract

The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total FGFBP1 in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentrations determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.

IPC Classes  ?

  • G01N 33/563 - Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

27.

LABORATORY APPARATUS, LABORATORY SAMPLE HANDLING SYSTEM AND USE OF A LABORATORY APPARATUS AND/OR A LABORATORY SAMPLE HANDLING SYSTEM

      
Application Number 18347647
Status Pending
Filing Date 2023-07-06
First Publication Date 2024-01-18
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Tropmann, Artur

Abstract

A laboratory apparatus for use in a laboratory sample handling system, wherein the apparatus comprises a cap waste disposal catcher, wherein the catcher is designed to catch a laboratory cap removed from a laboratory sample container containing a laboratory sample, and an electric field generator, wherein the generator is designed to generate an electric field to attract a residue of the sample released by the cap to the catcher.

IPC Classes  ?

  • G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
  • G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
  • B01L 9/06 - Test-tube stands; Test-tube holders

28.

METHOD OF OPERATING A LABORATORY SAMPLE DISTRIBUTION SYSTEM, LABORATORY SAMPLE DISTRIBUTION SYSTEM, AND LABORATORY AUTOMATION SYSTEM

      
Application Number EP2023069002
Publication Number 2024/013070
Status In Force
Filing Date 2023-07-10
Publication Date 2024-01-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Janner, Gabriele Piero
  • Oosterbroek, Edwin

Abstract

The disclosure refers to a method of operating a laboratory sample distribution system having a plurality of carriers (4) configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) assigned to the laboratory devices (3) and providing support to the plurality of carriers (4); and a driving device (13) configured to move, in response to driving control signals, the plurality of carriers (4) between plane positions (5) provided on the transport plane (1). The method comprises: prior to moving the carriers (4) on the transport plane (1), pre-determining off-line routes (6) on the transport plane (1) by one or more processors of a data processing device, the pre-determining comprising: determining a model representing the transport plane (1) with plane locations (5') and location-to-location movements between plane locations (5') associated to the plurality of carriers (4) calculating an optimized set of off-line routes between pairs of plane locations from the plurality of plane locations (5') using the model, the calculating comprising solving an optimization problem in which routes between the pairs of plane locations are simultaneously optimized; and providing the optimized set of off-line routes as off-line routes (6) on the transport plane (1); and controlling the driving device (13) such that the carriers (4) are moved along the pre-determined off-line routes (6) on the transport plane (1). Furthermore, a laboratory sample distribution system, and a laboratory automation system are provided.

IPC Classes  ?

  • G06Q 10/0835 - Relationships between shipper or supplier and carriers
  • B65G 54/02 - Non-mechanical conveyors not otherwise provided for electrostatic, electric, or magnetic
  • G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system

29.

METHOD OF OPERATING A LABORATORY SAMPLE DISTRIBUTION SYSTEM, LABORATORY SAMPLE DISTRIBUTION SYSTEM, AND LABORATORY AUTOMATION SYSTEM

      
Application Number EP2023069006
Publication Number 2024/013073
Status In Force
Filing Date 2023-07-10
Publication Date 2024-01-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Janner, Gabriele Piero
  • Ng, Cho Yiu
  • Ren, Shubin

Abstract

The disclosure refers to a method of operating a laboratory sample distribution system having: a plurality of carriers (4) having a number of n (n>3) carriers (4) each configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) configured to support to the plurality of carriers (4), wherein the transport plane (1) comprises a plurality of interconnected transport modules comprising a plurality of plane fields (5); and a driving device (13) configured to control movement of the plurality of carriers (4) along individual routes between the plurality of plane fields (5). The method com- prises: moving the plurality of carriers (4) along the individual routes on the transport plane (1), wherein the moving, for each carrier, comprises executing at least once steps of reserving a route segment along the individual route, the route segment being provided by one or more plane fields of the plurality of plane fields (5), and moving the carrier (4) along the route seg- ment; and preventing, for the plurality of carriers (4), a deadlock arrangement on the transport plane in which the plurality of carriers (4) block each other from further movement along the individual routes (6). The preventing is further comprising: determining, at a present operation time, a potential deadlock arrangement for the plurality of carriers (4) on the transport plane (1) at a future operation time, wherein the potential deadlock arrangement is assigned a number of n deadlock plane fields occupied by the plurality of carriers (4) in case of the potential dead- lock arrangement; for a first carrier from the plurality of carriers (4) moving along a first individ- ual route, reserving a first route segment ending with a first end plane field; and assigning a non-reserve flag to a next plane field which is next to the first end plane field along the first individual route. Further, a laboratory sample distribution system, and a laboratory automation system are provided.

IPC Classes  ?

  • G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
  • G06Q 10/0835 - Relationships between shipper or supplier and carriers
  • B65G 54/02 - Non-mechanical conveyors not otherwise provided for electrostatic, electric, or magnetic

30.

A METHOD FOR QUALITY CHECK OF AT LEAST ONE LC-MS MEASUREMENT

      
Application Number EP2023069339
Publication Number 2024/013240
Status In Force
Filing Date 2023-07-12
Publication Date 2024-01-18
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Laubender, Ruediger
  • Michely, Julian

Abstract

A method for quality check of at least one Liquid Chromatography-Mass Spectrometry (LC-MS) measurement on a sample comprising an analyte of interest and a defined amount of at least one internal standard is proposed. The method comprises the following steps a) (120) determining an information (peakAreaaqn) about an analyte signal and an information (peakAreatqn) about an internal standard signal of the LC-MS measurement; b) (122) determining at least one monitoring parameter by using the information about the analyte signal and the information about the internal standard signal by using at least one processing device (114), wherein the monitoring parameter comprises a minimal limit for the internal standard signal for said analyte signal of said sample; c) (124) comparing the information about the internal standard signal to the monitoring parameter by using the processing device (114), wherein the LC-MS measurement is flagged by using the processing device (114) as to fulfil the quality check in case the information about the internal standard signal is greater or equal to the monitoring parameter or otherwise as failed.

IPC Classes  ?

31.

DOOR MECHANISM DEVICE FOR A DOOR FOR A TRANSPORT APPARATUS FOR TRANSPORTING A SAMPLE CONTAINER CARRIER

      
Application Number EP2023069343
Publication Number 2024/013243
Status In Force
Filing Date 2023-07-12
Publication Date 2024-01-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Bates, Christopher
  • Gonzalez-Vila, Noelia
  • Pfaff, Julian

Abstract

A door mechanism device (110) for a door (100) for a transport apparatus (500) for trans- porting a sample container carrier is disclosed. The door mechanism device (110) comprises at least a first fixation bracket (112) configured for mounting the door mechanism device (110) to a frame of the transport apparatus, at least a first upper lever (114), at least a first lower lever (116), at least a first door mount (120) configured to be mounted to a cover (102) of a door (100) of the transport apparatus. The first upper lever (114) and the first lower lever (116) are rotatably mounted to the first fixation bracket (112) and the first door mount (120). The first upper lever (114) and the first lower lever (116) are rotatable around lever axes (122) such that the first door mount (120) is movable between a first position and a second position with the first door mount (120) substantially maintaining its orientation within a plane perpendicular to the lever axes (122). Further, a door (100) for a transport apparatus for transporting a sample container carrier and a transport apparatus (500) for transporting a sample container carrier are disclosed.

IPC Classes  ?

  • E05D 15/40 - Suspension arrangements for wings supported on arms movable in vertical planes
  • E05D 15/46 - Suspension arrangements for wings supported on arms movable in vertical planes with two pairs of pivoted arms
  • E05F 5/00 - Braking devices, e.g. checks; Stops; Buffers
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

32.

METHOD AND SYSTEM OF MANAGING SAMPLE PRIORITIES

      
Application Number 18360278
Status Pending
Filing Date 2023-07-27
First Publication Date 2024-01-11
Owner
  • Roche Diagnostics Operations, Inc. (USA)
  • Hitachi High-Tech Corporation (Japan)
Inventor
  • Laubert, Daniel
  • Sachse, Rita
  • Aldorf, Dennis
  • Rapp, Werner
  • Herzog, Ralf
  • Yagi, Kenichi
  • Chida, Satoru

Abstract

The present disclosure relates to a computer implemented method of managing sample processing priorities in a diagnostic laboratory comprising at least one sample processing device connected to a host system. The method comprises generating a communication message between the host system and the at least one sample processing device related to a sample processing order received in association with a sample, the message comprising one of at least two priority identifiers (R, S) indicative of respective sample processing priorities from lower priority to higher priority according to the received sample processing order. The method further comprises identifying the sample by the at least one sample processing device and processing the sample by the at least one sample processing device according to the sample processing priority (S, R) in the message. In case of receiving a subsequent request for change of sample processing priority for the sample from a lower priority to a higher priority after transmission of the message and before the sample is processed, the method comprises changing the message and processing the sample as a higher priority sample instead of as a lower priority sample, wherein changing the message comprises changing the lower priority identifier (R) to an identifier (CS) indicative of a change of priority but different from an equivalent higher priority identifier (S) in order to maintain the sample and the sample processing order uniquely identifiable and traceable by both the host system and the at least one sample processing device. A respective system for managing sample processing priorities is herein also disclosed.

IPC Classes  ?

  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G06F 9/48 - Program initiating; Program switching, e.g. by interrupt
  • G06F 9/54 - Interprogram communication

33.

SAFE POINT PATTERN

      
Application Number EP2023067432
Publication Number 2024/003030
Status In Force
Filing Date 2023-06-27
Publication Date 2024-01-04
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Oosterbroek, Edwin
  • Schnarwiler, Dominik
  • Sillitoe, Nicolas Seungoon

Abstract

A method of operating a distribution system (110), wherein the distribution system (110) comprises - a number of carriers (112) configured for carrying one or more objects (114), - a transport plane (122) configured for supporting the carriers (112), wherein the transport plane (122) comprises a plurality of transport modules (124), wherein a grid (126) of logical positions (128) is defined on the transport plane (122), - a drive system (130) configured for moving the carriers (112) on the transport plane (122) between the logical positions (128), - a control system (136) configured for controlling the drive system (130), wherein the control system (136) comprises a routing system (138) configured for calculating routes for the carriers (112), wherein the method comprises the steps: a) defining a global pattern of safe points (148) and applying the global pattern on the transport plane (122) by using the routing system (138), wherein safe points (148) are logical positions (128) selected in view of a range of motion for a carrier (112) occupying said logical position (128) such that on the safe points (148) a carrier (112) can be placed and can be moved away again, wherein the global pattern is applied onto the transport plane (122) independently of module boundaries; b) calculating partial routes for the carriers (112) so that an end position of each partial route is either one of the safe points (148) or has a free path to one of the safe points (148) to be reachable in the next partial route by using the routing system (138). Further, a distribution system (110) and a computer program and a computer-readable storage medium for performing the method according to the present invention are disclosed.

IPC Classes  ?

  • G01N 15/04 - Investigating sedimentation of particle suspensions
  • B65G 35/06 - Mechanical conveyors not otherwise provided for comprising a load-carrier moving along a path, e.g. a closed path, and adapted to be engaged by any one of a series of traction elements spaced along the path
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
  • G06Q 10/08 - Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
  • G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system

34.

DISTRIBUTION SYSTEM AND METHOD FOR DISTRIBUTING A PLURALITY OF CARRIERS

      
Application Number EP2023067433
Publication Number 2024/003031
Status In Force
Filing Date 2023-06-27
Publication Date 2024-01-04
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Oosterbroek, Edwin
  • Sillitoe, Nicolas Seungoon

Abstract

A distribution system (110) and a method for distributing a plurality of carriers (114) using the distribution system (110) are disclosed. The distribution system (110) comprises: - at least one transport plane (118) comprising logical positions (120); - a plurality of carriers (114) for transporting objects (122); - at least one drive system (126) for moving the carriers (114) on the transport plane (118) between the logical positions (120); and - at least one control system (128) configured for controlling the carriers (114) to move on a planned route from a start position to a final destination position on the transport plane (118), wherein the planned route comprises partial routes (144), wherein the control system (128) comprises at least one routing system (130) configured for calculating routing plans for carriers (114) on the transport plane (118) by modeling the transport plane (118) with graph of nodes (132), wherein the routing system (130) is configured for calculating the routing plans considering moving time periods (160) and waiting time periods (162), wherein the routing system (130) is configured for assigning waiting time periods (162) for carriers (114) depending on a reservation of logical positions (120) of the partial routes (144) of other carriers (114), wherein, if a carrier (114) experiences a time delay (158) during execution of a move, the routing system (130) is configured for shifting the experienced time delay (158) to at least one upcoming waiting time period (166) of a carrier (114).

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
  • B65G 35/06 - Mechanical conveyors not otherwise provided for comprising a load-carrier moving along a path, e.g. a closed path, and adapted to be engaged by any one of a series of traction elements spaced along the path
  • G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
  • G06Q 10/08 - Logistics, e.g. warehousing, loading or distribution; Inventory or stock management

35.

METHOD FOR DIAGNOSING ENDOMETRIOSIS AND FOR CLASSIFYING THE STAGE OF ENDOMETRIOSIS

      
Application Number EP2023067108
Publication Number 2023/247752
Status In Force
Filing Date 2023-06-23
Publication Date 2023-12-28
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Flohr, Aljoscha Michael
  • Georgopoulou, Aikaterini
  • Guennoun, Rym
  • Hund, Martin
  • Klammer, Martin

Abstract

The present invention relates to methods of diagnosing whether a subject has endometriosis, to methods of classifying the stage of endometriosis, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, and methods of monitoring endometriosis progression in a subject, by determining the amount or concentration of c-Kit in a sample of the subject, and comparing the determined level to a reference value.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

36.

AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD

      
Application Number 18339760
Status Pending
Filing Date 2023-06-22
First Publication Date 2023-12-28
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Epping, Claudia
  • Rempt, Martin

Abstract

The present invention relates to a clinical diagnostic system, a method for determining the presence or level of at least one analyte of interest in a biological sample, a kit and the uses thereof for efficiently and/or robust detection of an analyte of interest.

IPC Classes  ?

37.

SARS-COV-2 NUCLEOCAPSID ANTIBODIES

      
Application Number 18251393
Status Pending
Filing Date 2021-10-29
First Publication Date 2023-12-21
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Gerg, Michael
  • Jucknischke, Ute
  • Kurtkaya, Ulrike
  • Mock, Thomas
  • Schraeml, Michael
  • Stiegler, Sandrine Carolina

Abstract

The present invention relates to monoclonal antibodies binding to the nucleocapsid protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, as well as methods of detecting SARS-CoV-2 virus in a sample comprising using said antibodies.

IPC Classes  ?

  • C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

38.

A METHOD FOR MULTIPLE REACTION MONITORING USING A MASS SPECTROMETRY DEVICE

      
Application Number EP2023065435
Publication Number 2023/237709
Status In Force
Filing Date 2023-06-09
Publication Date 2023-12-14
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Lang, Robert
  • Mitra, Indranil

Abstract

A method for multiple reaction monitoring using a mass spectrometry device (106) is proposed. The method comprises the following steps: i) (128) measuring, by using the mass spectrometry device (106), multiple reaction monitoring transitions of quantifier and qualifier of both an internal standard and an analyte using staggered- multiple reaction monitoring, wherein the staggered-multiple reaction monitoring comprises at least three multiple reaction monitoring channel groups, wherein one of the multiple reaction monitoring channel groups measure at respective theoretical m/z values of the quantifier and qualifier of both the internal standard and the analyte and the two other multiple reaction monitoring channel groups measure at respective m/z values shifted to higher and lower values by a predefined level; ii) (130) comparing, for at least two groups, at least two of the quantifier/qualifier ratios of the multiple reaction monitoring transitions of the internal standard with a reference value from a database (126) by using at least one processing device (120), wherein the comparison comprises determining a deviation between the quantifier/qualifier ratios and the reference value; iii) (132) determining from the analyte and the internal standard measured multiple reaction monitoring transitions a measurement result by using the processing device (120), if the deviation for at least one of the quantifier/qualifier ratios is within at least one predefined tolerance range, otherwise rejecting (136) the measured multiple reaction monitoring transitions.

IPC Classes  ?

  • H01J 49/00 - Particle spectrometers or separator tubes

39.

METHOD FOR DETERMINING THE SYSTEM RESISTANCE OF A DEVICE

      
Application Number 18448566
Status Pending
Filing Date 2023-08-11
First Publication Date 2023-12-07
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Lambertson, Michael

Abstract

A method for determining system resistance of at least one power supply of a handheld medical device, the method including: a) generating at least one excitation voltage signal, wherein the excitation voltage signal comprises at least one direct current (DC) voltage signal, wherein the excitation voltage signal has a fast transition DC flank of 20 ns or less; b) applying the excitation voltage signal to at least one reference resistor having a predetermined or pre-defined resistance value, wherein the reference resistor is arranged in series with the power supply; c) measuring a response signal of the power supply; d) determining a signal flank from the response signal and determining an ohmic signal portion from one or both of shape and height of the signal flank; and e) determining the system resistance of the power supply from the ohmic signal portion.

IPC Classes  ?

  • G01R 27/14 - Measuring resistance by measuring current or voltage obtained from a reference source
  • G01R 31/36 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC]

40.

AN IMPROVED METHOD OF CONVERTING VENOUS BLOOD GAS VALUES TO ARTERIAL BLOOD GAS VALUES

      
Application Number EP2023064693
Publication Number 2023/232945
Status In Force
Filing Date 2023-06-01
Publication Date 2023-12-07
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor Flou, Bjarne

Abstract

A computer-implemented method, system and decision support system adapted to provide arterial venous blood gas values without the provision of an arterial oxygenation saturation value or arterial blood gas values. The method comprises the provision of arterial blood gas values from a subject, for which said subject, only venous blood gas values are provided, by providing a mathematical model adapted to convert said venous blood gas values with a provided predefined default arterial oxygenation value to output arterial blood gas values of said subject. The present invention thus provides a method for providing arterial blood gas values from a specific subject without the need of providing an arterial blood sample from a painful arterial blood draw or the need for an arterial oxygenation saturation value of the subject, thus reducing distress to said patient and a reduction of tasks to relevant health care personnel.

IPC Classes  ?

  • A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
  • G01N 33/49 - Physical analysis of biological material of liquid biological material blood

41.

ELECTROCHEMICAL REGENERATION OF IMMUNOSENSORS

      
Application Number EP2023064802
Publication Number 2023/232994
Status In Force
Filing Date 2023-06-02
Publication Date 2023-12-07
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Filsinger, Ines
  • Gutierrez-Sanz, Oscar
  • Lopez-Calle, Eloisa
  • Thakur, Bhawana

Abstract

The present invention concerns the field of re-usable immunosensors. In particular, it relates to a method for regenerating an immunosensor comprising at least one polypeptide attached to an electroconductive surface of said immunosensor, wherein the at least one polypeptide is capable of specifically binding an analyte to be detected by the immunosensor, said method comprising the step of applying to the immunosensor at a temperature selected from the temperature range from about 35°C to about 42°C a positive electrical potential of about 0.3 V on said electroconductive surface of the immunosensor for a time sufficient to allow regeneration. Moreover, it also relates to a regenerated immunosensor obtainable by the method of the present invention and a system and device comprising the immunosensor as described herein, wherein said device is capable of applying a positive electrical potential of about 0.3 V on said electro conductive surface of the immunosensor for a time sufficient to allow regeneration. The present invention also contemplates, in general, the use of a temperature selected from the temperature range from about 35°C to about 42°C and a positive electrical potential of about 0.3 V on an electro conductive surface of an immunosensor as described in any one of claims 1 to 13 for regeneration of said immunosensor.

IPC Classes  ?

  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

42.

SAMPLE CONTAINER HOLDING AND/OR TRANSPORTING DEVICE

      
Application Number 18325328
Status Pending
Filing Date 2023-05-30
First Publication Date 2023-11-30
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Baeurer, Michael
  • Pristat-Gupta, Andre

Abstract

The disclosure relates to a sample container holding and/or transporting device having an aperture with a longitudinal axis, which aperture is configured for receiving a sample container, wherein a biasing structure is provided in the aperture, which comprises a plurality of elastically deflectable nubs, wherein the nubs are distributed spatially discrete along the longitudinal axis of the aperture. The disclosure further relates to a use of a structure having nubs as a biasing structure in a sample container holding and/or transporting device, and to a laboratory automation system comprising a sample container holding and/or transporting device.

IPC Classes  ?

  • B01L 9/06 - Test-tube stands; Test-tube holders

43.

METHOD FOR PREPARING HIGHLY POROUS POLYMER PARTICLES FOR DIAGNOSTIC APPLICATIONS

      
Application Number 18338633
Status Pending
Filing Date 2023-06-21
First Publication Date 2023-11-30
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Silvestre, Martin Eduardo
  • Hug, Stephan

Abstract

The present disclosure relates to a method of preparing a magnetic particle having a polymer matrix (P) and at least one magnetic core (M), preferably at least two magnetic cores (M), wherein the polymer matrix (P) comprises at least one hypercrosslinked polymer, wherein the method comprises (i) providing at least one magnetic core (M), preferably at least two magnetic cores (M), (ii) providing polymer precursor molecules, (iii) polymerizing the polymer precursor molecules according to (ii) in the presence of the at least one magnetic core (M), thereby forming a particle comprising the at least one magnetic core (M). Further, the present disclosure relates to particles obtained or obtainable by this method as well as to the use of these particles. In a further aspect, the disclosure relates to a method for determining at least one analyte in a fluid sample having the step of contacting of the magnetic particle with a fluid sample having or suspected of having the at least one analyte.

IPC Classes  ?

  • B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
  • B01J 20/26 - Synthetic macromolecular compounds
  • B01J 20/32 - Impregnating or coating
  • B03C 1/01 - Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

44.

COLUMN DEVICE

      
Application Number 18447604
Status Pending
Filing Date 2023-08-10
First Publication Date 2023-11-30
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Kupser, Peter
  • Leinenbach, Andreas

Abstract

A column device for an automatic analyser. The automatic analyzer comprises a high performance liquid chromatography (HPLC) module. The HPLC module comprises a fixation device configured to automatically fix and release a chromatographic column. The column device comprises a column jacket and a capillary. The capillary comprises predetermined dimensions and is disposed within the column jacket. The column device is configured to be installed at the HPLC module using the fixation device. Further, an automatic analyzer is disclosed.

IPC Classes  ?

  • G01N 30/16 - Injection
  • G01N 30/60 - Construction of the column
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

45.

BACTERIAL PILUS PROTEIN COMPLEX FIMGT-DSF STABILIZED PROTEIN COMPLEXES FOR PRODUCING FILAMENTOUS PHAGES

      
Application Number 18028245
Status Pending
Filing Date 2021-09-28
First Publication Date 2023-11-30
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Boenitz-Dulat, Mara
  • Schraeml, Michael
  • Woersdoerfer, Bigna

Abstract

The present invention relates to bacterial pilus protein complex FimGt-DsF stabilized protein complexes for producing phagemids or filamentous phages, and methods for use of these.

IPC Classes  ?

  • C07K 14/245 - Escherichia (G)
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

46.

GRIPPING APPARATUS FOR GRIPPING SAMPLE CONTAINER

      
Application Number 18299750
Status Pending
Filing Date 2023-04-13
First Publication Date 2023-11-23
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Addihalli Narayana, Avinash
  • Gutmann, Timo
  • Kollmer, Markus
  • Kraetschmer, Marius
  • Kulitskyi, Andrii
  • Leontjevs, Vladimirs
  • Pauls, Jan

Abstract

A gripping apparatus for gripping a sample container comprising: a gripper body comprising a gripper actuator; at least two gripper fingers each comprising a gripping surface, wherein at least one of the gripper fingers is movably coupled to the gripper body, and wherein the gripping apparatus is designed for gripping a sample container with the gripping surfaces of the at least two gripper fingers by moving the at least one movable gripper finger; and characterized in that the gripping apparatus comprises at least one elastically mounted contacting surface for elastically contacting a sample container about to be gripped by the gripping apparatus.

IPC Classes  ?

47.

High Affinity Antibodies Specifically Binding to α-1,6-Core-Fucosylated Alpha-Fetoprotein

      
Application Number EP2023062762
Publication Number 2023/222543
Status In Force
Filing Date 2023-05-12
Publication Date 2023-11-23
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Gerg, Michael
  • Hillringhaus, Lars
  • Jucknischke, Ute
  • Muth, Anna
  • Oelschlaegel, Tobias
  • Pinchuk, Boris
  • Schraeml, Michael
  • Siebenhaar, Joanna
  • Thirault, Laurence

Abstract

The present invention relates to monoclonal antibodies and antigen binding fragments that specifically bind to α-1,6-core-fucosylated alpha-fetoprotein (AFP), which is the core component of AFP-L3. Thus, the antibodies and antigen binding fragments provided herein may also be referred to as AFP-L3 antibodies. Also provided are polynucleotides encoding the antibodies or antigen binding fragments of the invention, host cells expressing the antibodies and antigen binding fragments of the invention, methods for producing the antibodies and antigen binding fragments of the invention, and uses of the antibodies and antigen binding fragments of the invention. Also provided herein is a pretreatment agent facilitating the binding of the antibodies and antigen binding fragments of the invention to α-1,6-core-fucosylated AFP. The present invention further relates to kits comprising the antibodies and antigen binding fragments of the invention and optionally the pretreatment agent of the invention.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

48.

METHOD FOR OPERATING A SORTER DEVICE IN AN IVD LABORATORY SYSTEM AND IVD LABORATORY SYSTEM

      
Application Number EP2023062343
Publication Number 2023/217815
Status In Force
Filing Date 2023-05-10
Publication Date 2023-11-16
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Lambaek, Ole
  • Schesny, Andreas

Abstract

The present disclosure refers to a method for operating a sorter device (5) in an IVD laboratory system, the method comprising providing a sorter device (5) in an IVD laboratory system (1) provided with a system operation controller (3), the sorter device (5) having a plurality of sample container racks each provided with reception holes for receiving sample containers (4), a handling device configured to pick sample containers (4) from and place sample containers (4) in the reception holes of the sample container racks, a sorter device controller configured to control operation of the sorter device (5) and connectable to the system operation controller (3), and an output device functionally connected to the sorter device controller and configured to output at least one of audio data and video data. The sorter device (5) is configured in a pre-operation process, the configuring comprising: assigning the plurality of sample container racks to a plurality of processing sub-targets conducted by the IVD laboratory system (1) in operation, wherein a first sample container rack is assigned to a first processing sub-target and a second sample container rack is assigned to a second processing sub-target which is different from the first processing sub- target, and assigning to the first sample container rack a first threshold value indicative of a first threshold number of sample containers (4) in the first sample container rack, wherein the first threshold number of sample containers (4) is smaller than a maximum number of sample containers (4) receivable in the first sample container rack. The sorter device (5) is operated in an operation process, the operating comprising: placing sample containers (4) in the reception holes of the first sample container rack by the handling device, determining a first present number of sample containers (4) received in the first sample container rack by the sorter device controller, comparing the first present number of sample containers (4) to the first threshold value by the sorter device controller, and if the first present number of sample containers (4) is equal to or greater than the first threshold value, outputting a first warning data through the output device. Furthermore, an IVD laboratory system (1) is provided.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

49.

LABORATORY DATA MANAGEMENT SYSTEM

      
Application Number 18360355
Status Pending
Filing Date 2023-07-27
First Publication Date 2023-11-16
Owner
  • Roche Diagnostics Operations, Inc. (USA)
  • Hitachi High-Tech Corporation (Japan)
Inventor
  • Allwinn, Richard
  • Seyffert, Sascha
  • Huser, Ronald
  • Bitzer, Andre
  • Schweighauser, Stephan
  • Koizumi, Nobuhiro
  • Seki, Yoshihiro

Abstract

The present disclosure relates to a laboratory data management system 100 comprising a data source layer 10 comprising at least one laboratory device 11, 12, 13, 14, 15 as a data source, a data adapter layer 20 comprising at least one data source agent 21, 22, 23, 24, 25 configured to obtain data from the at least one data source and to convert the data from a data source format to a data-source independent format, a consumer layer 30 configured for installation and/or execution of consumer application software 31, 32, 33, 34, and a data management layer 40 between the data adapter layer 20 and the consumer layer 30. The data management layer 40 comprises a data storage 50 configured to store data 1-n converted by the at least one data source agent 21, 22, 23, 24, 25, at least one data manager 41, 42, 43, 44 programmed to execute instructions from the consumer application software 31, 32, 33, 34, which when executed cause the at least one data manager 41, 42, 43, 44 to select application-specific data in the data storage 50 and to make them accessible to a consumer via the consumer application software 31, 32, 33, 34 in a consumer format. The data adapter layer 20 and the data management layer 40 are arranged in a laboratory gateway 60 connected to the data-source layer 10 and to the consumer layer 30.

IPC Classes  ?

  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades

50.

CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION

      
Application Number 18028235
Status Pending
Filing Date 2021-09-30
First Publication Date 2023-11-16
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Karl, Johann
  • Kastner, Peter
  • Latini, Roberto
  • Masson, Serge
  • Meessen, Jennifer Marie Theresia Anna
  • Rolny, Vinzent
  • Wienhues-Thelen, Ursula-Henrike
  • Ziegler, André

Abstract

The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.

IPC Classes  ?

  • G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones

51.

METHOD FOR DETERMINING A DILUTION FACTOR OF A SAMPLE

      
Application Number EP2023061220
Publication Number 2023/213702
Status In Force
Filing Date 2023-04-28
Publication Date 2023-11-09
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor Vondenhoff, Gaston Hubertus Maria

Abstract

samplecalibration,avsamplecalibration,avcalibration,av by using the processing device (130).

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G01N 30/06 - Preparation
  • G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
  • G01N 1/38 - Diluting, dispersing or mixing samples
  • G01N 30/72 - Mass spectrometers

52.

HEMOLYSIS AND DERIVATIZATION REAGENTS AND METHODS FOR DETERMINING LACTONE ANALYTES

      
Application Number EP2023061358
Publication Number 2023/213731
Status In Force
Filing Date 2023-04-28
Publication Date 2023-11-09
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Stueckl, Tobias
  • Vondenhoff, Gaston Hubertus Maria

Abstract

The present invention relates to a method for determining a lactone analyte in a sample, comprising (i) contacting said sample with a derivatization reagent comprising a nucleophilic reagent; (ii) determining a nucleophilic reagent-derivative of said lactone analyte obtained in step (i), and (iii) determining said lactone analyte based on the determination of the nucleophilic reagent-derivative of said lactone analyte in step (ii). The present invention also relates to methods uses, compounds, kits and devices related thereto.

IPC Classes  ?

  • G01N 33/94 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics

53.

METHOD FOR ESTABLISHING METROLOGICAL TRACEABILITY FOR AT LEAST ONE IN VITRO DIAGNOSTIC MEDICAL DEVICE

      
Application Number EP2023061804
Publication Number 2023/213945
Status In Force
Filing Date 2023-05-04
Publication Date 2023-11-09
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Geistanger, Andrea
  • Hilger, Anton
  • Intelmann, Daniel

Abstract

ƒpp cƒpp PP ≥ 1. In each adjustment step a signal adjustment function or a concentration adjustment function is determined and at least one target concentration value is assigned.

IPC Classes  ?

  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

54.

PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE

      
Application Number 18352183
Status Pending
Filing Date 2023-07-13
First Publication Date 2023-11-09
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Mang, Anika
  • Muley, Thomas
  • Rolny, Vinzent
  • Wehnl, Birgit

Abstract

The present invention relates to an in vitro method for assessing the risk of non-small cell lung carcinoma (NSCLC) disease progression for a subject classified to have stable disease under an ongoing NSCLC treatment regime. The method involves determining the level of CYFRA 21-1 and/or the level of CA 125 in a sample obtained from the subject; and comparing (i) the determined level of CYFRA 21-1 to a CYFRA 21-1 cut-off level, (ii) the determined level of CA 125 to a CA 125 cut-off level, or (iii) a score taking into account the determined level of CYFRA 21-1 and/or the determined level of CA 125 to a cut-off score. The method of the invention further allows for assessing whether the subject responds to the ongoing treatment and/or whether the treatment regime should be maintained or modified. The invention also provides for corresponding uses, computer-implemented methods and computer program products.

IPC Classes  ?

  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

55.

METHODS AND SYSTEMS FOR PROCESSING DATA OF AN ANALYTICAL INSTRUMENT FOR ANALYZING BIOLOGICAL SAMPLES

      
Application Number 18353378
Status Pending
Filing Date 2023-07-17
First Publication Date 2023-11-09
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Suter, Urs
  • Morcillo Montejo, Alejandro
  • Tienda Fernandez, Antonio
  • Martin, Stephen

Abstract

A method for processing data of an analytical instrument for analyzing biological samples is presented. The method comprises receiving instrument data from the analytical instrument at a data processing module communicatively connected with the analytical instrument, generating metadata from the received instrument data at the data processing module, applying a first encryption to the instrument data at the data processing module, applying a second encryption to the generated metadata at the data processing module, and transmitting the encrypted metadata and encrypted instrument data to a remote server. The remote server and the data processing module are communicatively connected. The method also comprises removing the second encryption from the metadata at the remote server and forwarding the instrument data encrypted by the first encryption from the remote server to a management system of the analytical instrument.

IPC Classes  ?

  • H04L 9/40 - Network security protocols
  • G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
  • G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
  • H04W 12/033 - Protecting confidentiality, e.g. by encryption of the user plane, e.g. user’s traffic
  • H04L 67/561 - Adding application-functional data or data for application control, e.g. adding metadata
  • H04L 67/565 - Conversion or adaptation of application format or content
  • H04L 9/08 - Key distribution
  • H04L 9/14 - Arrangements for secret or secure communications; Network security protocols using a plurality of keys or algorithms
  • H04L 9/30 - Public key, i.e. encryption algorithm being computationally infeasible to invert and users' encryption keys not requiring secrecy

56.

METHOD AND LABORATORY SYSTEM FOR DETERMINING AT LEAST ONE CONTAINER INFORMATION ABOUT A LABORATORY SAMPLE CONTAINER

      
Application Number EP2023061331
Publication Number 2023/213723
Status In Force
Filing Date 2023-04-28
Publication Date 2023-11-09
Owner
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
Inventor
  • Rein, Michael
  • Wiegand, Friederike

Abstract

The invention relates to a method for determining at least one container information (coi) about a laboratory sample container (1), wherein the method comprises the steps: a) acquiring an image (ibc) comprising a brightness and/or color information (bci) of a possible region (2) of the container (1), b) acquiring a map (md) comprising a depth information (di) of the region (2), and c) determining the container information (coi) by fusing the brightness and/or color information (bci) and the depth information (di).

IPC Classes  ?

  • G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level

57.

HIV GP41 VARIANTS FOR IMMUNODIAGNOSTIC ASSAYS

      
Application Number EP2023061443
Publication Number 2023/213758
Status In Force
Filing Date 2023-05-02
Publication Date 2023-11-09
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Benz, Juliane
  • Boenitz-Dulat, Mara
  • Gloeck, Mario
  • Muench, Peter
  • Poehlmann, Daniela
  • Riedel, Alexander

Abstract

The invention relates to novel HIV gp41 antigen compositions that are suitable for detecting antibodies against HIV in an isolated biological sample providing high specificity immunoassay results. It further relates to methods detecting HIV antibodies, use of novel HIV gp41 antigen compositions in immunoassays as well as to reagent kits comprising novel HIV gp41 antigen compositions.

IPC Classes  ?

  • C07K 14/16 - HIV-1
  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

58.

POSITION TRACKING SYSTEM AND METHOD FOR TRACKING A RELATIVE POSITION OF CONNECTED MODULES

      
Application Number EP2023061962
Publication Number 2023/214025
Status In Force
Filing Date 2023-05-05
Publication Date 2023-11-09
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Leontjevs, Vladimirs
  • Riedel, Philipp

Abstract

A position tracking system (112) for tracking a relative position between at least two connected modules (114) is disclosed. The position tracking system (112) comprises: - at least one target (118) associated with a first one of the at least two connected modules (114), wherein the at least one target (118) is at least one of arrangeable on and arrangeable within the first one of the at least two connected modules (114), wherein the at least two connected module (114) are mechanically interacting entities and/or components, configured for allowing transport of objects from one module to the other module; - at least one position sensor (120) associated with a second one of the at least two connected modules (114), wherein the position sensor (120) is configured for generating at least one sensor signal according to a relative position between the at least one position sensor (120) and the at least one target (118), wherein the at least one position sensor (120) is at least one of arrangeable on and arrangeable within the second one of the at least two connected modules (114); - at least one processing unit (122) configured for tracking a relative position between the connected modules (114) from the at least one sensor signal in at least one plane (124); and - at least one further sensor (140) configured for generating a further sensor signal according to at least one further parameter, wherein the further sensor (140) is selected from the group consisting of: a temperature sensor (142) and/or a humidity sensor, wherein the processing unit (122) is further configured for considering the at least one further sensor signal when determining the relative position between the connected modules (114). Further disclosed are a monitoring system (110) for monitoring at least two connected modules (114), method for tracking a relative position between at least two connected modules (114) by using at least one position tracking system (112) and a method for monitoring at least two connected modules (114) by using at least one monitoring system (110).

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system

59.

GLYCAN STRUCTURES OF HAPTOGLOBIN AS A BIOMARKER OF HEPATOCELLULAR CARCINOMA

      
Application Number EP2023061068
Publication Number 2023/209067
Status In Force
Filing Date 2023-04-27
Publication Date 2023-11-02
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Busskamp, Holger
  • Kohansal Nodehi, Mahdokht
  • Kroeniger, Konstantin
  • Rolny, Vinzent
  • Swiatek-De Lange, Magdalena
  • Tabares, Gloria

Abstract

The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject comprising determining the amount of one or more glycan structure at position N207 of haptoglobin (i.e. of the B-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject. Also disclosed are a glycan structure as well as a glycopeptide comprising said glycan structure, both of great utility in the detection of HCC. Further, the present invention relates to the use of one or more glycan structure at position N207 or of a glycopeptide comprising N207 of haptoglobin in combination with AFP and/or PIVKA in the detection of HCC.

IPC Classes  ?

  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

60.

CHIRAL SEPARATION OF N-PHTHALOYL-D/L-GLUTAMIC ACID

      
Application Number EP2023058349
Publication Number 2023/208514
Status In Force
Filing Date 2023-03-30
Publication Date 2023-11-02
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Rempt, Martin
  • Collins, Manuela

Abstract

A method of separating stereoisomers of N-phthaloyl-glutamic acid is described. The method comprises passing a solution comprising an L/D stereoisomer mixture of N-phthaloyl-glutamic acid through a chiral chromatography column by normal phase chromatography, wherein the chiral chromatography column comprises, as a stationary phase, silica having groups represented by formula (1) as described herein covalently bonded to a surface thereof.

IPC Classes  ?

  • B01D 15/32 - Bonded phase chromatography, e.g. with normal bonded phase, reversed phase or hydrophobic interaction
  • B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
  • B01J 20/24 - Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
  • B01J 20/29 - Chiral phases
  • B01J 20/289 - Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
  • B01J 20/285 - Porous sorbents based on polymers
  • C12P 13/14 - Glutamic acid; Glutamine

61.

GLYCAN STRUCTURES OF HAPTOGLOBIN AS A BIOMARKER OF HEPATOCELLULAR CARCINOMA

      
Application Number EP2023061066
Publication Number 2023/209065
Status In Force
Filing Date 2023-04-27
Publication Date 2023-11-02
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Rolny, Vinzent
  • Busskamp, Holger
  • Kroeniger, Konstantin
  • Kohansal Nodehi, Mahdokht
  • Swiatek-De Lange, Magdalena
  • Tabares, Gloria

Abstract

The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject. The method may comprise determining the amount of one or more N-glycan structure attached to haptoglobin (i.e. of the β- chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject and comparing the amount of said one or more glycan structure to a reference amount of said one or more glycan structure, wherein an altered amount of said one or more glycan structure in said patient sample relative to the reference amount of said one or more glycan structure is indicative for HCC. Further, the present invention relates to the use of one or more glycan structure attached to haptoglobinor of a glycopeptide derived from haptoglobin in combination with AFP and/or PIVKA-II in the detection of HCC.

IPC Classes  ?

  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

62.

ANTIBODIES SPECIFIC FOR ALPHA-1,6-CORE-FUCOSYLATED PSA AND FUCOSYLATED FRAGMENTS THEREOF

      
Application Number 18187502
Status Pending
Filing Date 2023-03-21
First Publication Date 2023-10-26
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Swiatek-De Lange, Magdalena
  • Siebenhaar, Joanna
  • Jones, Carol
  • Pritchett, Thomas
  • Muranyi, Andrea
  • Hojer, Caroline Dorothea
  • Gerg, Michael
  • Hillringhaus, Lars
  • Tabares, Gloria
  • Roessler, Christian
  • Schraeml, Michael
  • Singh, Shalini
  • Kott, Theresa

Abstract

The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to α-1,6-core-fucosylated prostate specific antigen (PSA) and partial sequences thereof comprising the α-1,6-core-fucose residue. The antibodies and antigen binding fragments significantly discriminate between core-fucosylated PSA or core-fucosylated PSA partial sequences and other glycosylated PSA species and partial sequences thereof lacking the core-fucose residue, including aglycosylated PSA, as well as core-fucosylated glycan in other contexts. The present invention further relates to nucleic acid molecules encoding the light chain variable region or the heavy chain variable region of the antibody of the invention, as well as vectors comprising said nucleic acid molecules. The invention also relates to a host cell comprising the vector(s) of the invention, as well as to methods for the production of an antibody or antigen binding fragment of the invention comprising culturing the host cell of the invention under suitable conditions and isolating the antibody produced. Furthermore, the present invention relates to an antibody obtainable by the method of the invention, to a composition comprising at least one of the antibody or antigen binding fragment of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the antibody produced by the method of the invention. The present invention also relates to the use of an antibody or antigen binding fragment of the invention for detecting and discriminating core-fucosylated PSA or core-fucosylated partial sequences thereof in biological samples.

IPC Classes  ?

  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N 1/30 - Staining; Impregnating

63.

AUTOMATIC ANALYZER

      
Application Number 17792215
Status Pending
Filing Date 2020-12-14
First Publication Date 2023-10-26
Owner
  • HITACHI HIGH-TECH CORPORATION (Japan)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Mizuki, Yusuke
  • Nakai, Marina
  • Sasaki, Shunsuke
  • Imai, Kenta
  • Seiler, Alexander
  • Ehrlich-Weinreich, Gertraud

Abstract

An automatic analyzer is capable of reducing the time required for a series of maintenance operations in that the user’s maintenance work is linked to the device driving so that the maintenance work proceeds in the order of the maintenance work tools. An automatic analyzer includes a plurality of processing units for processing a specimen: an agitation mechanism, a reagent dispensing mechanism, a mixer, an incubator, and a specimen dispensing mechanism. A control unit controls a processing unit, an analysis unit, and a display unit and causes the display unit to display a plurality of maintenance work tools used for maintenance work performed by the operator on the plurality of processing units and to display the maintenance work contents of the plurality of processing units that continuously use one of the plurality of maintenance work tools, selected by the operator via the display unit.

IPC Classes  ?

  • G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
  • G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

64.

ESM-1 FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE

      
Application Number 18021047
Status Pending
Filing Date 2021-08-12
First Publication Date 2023-10-26
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Rolny, Vinzent
  • Wienhues-Thelen, Ursula-Henrike
  • Ziegler, Andre
  • Conen, David
  • Osswald, Stefan
  • Kuehne, Michael
  • Kastner, Peter

Abstract

The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of the biomarker ESM-1 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

65.

DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY

      
Application Number 18306195
Status Pending
Filing Date 2023-04-24
First Publication Date 2023-10-19
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Heindl, Dieter
  • Kobold, Uwe
  • Rempt, Martin
  • Zuth, Christoph

Abstract

The present invention relates to a method, a diagnostic system, a kit and the use thereof for efficiently detection of an analyte of interest by nanoESI mass spectrometry.

IPC Classes  ?

  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones

66.

INTERFERENCE MONITORING FOR PROVIDING A VERIFIED ANALYTE MEASUREMENT

      
Application Number 18333347
Status Pending
Filing Date 2023-06-12
First Publication Date 2023-10-19
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Intelmann, Daniel
  • Heiss, Peter

Abstract

The present invention relates to a method for providing a verified analyte measurement of a sample with a chromatography mass spectrometer device, said method comprising the following steps: a) admixing an interferent monitoring compound and, optionally an internal standard, to the sample; b) determining a chromatogram of the sample by acquiring a plurality of data points for signal intensities over time for said interferent monitoring compound, said analyte, and optionally said internal standard; and c) comparing a property of an interferent monitoring compound peak to a property of an internal standard peak and/or to a property of an analyte peak; and to methods and systems related thereto.

IPC Classes  ?

  • G01N 33/96 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
  • G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
  • G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones
  • G01N 30/72 - Mass spectrometers
  • G01N 30/86 - Signal analysis

67.

EVAPORATION-BASED SAMPLE PREPARATION WORKFLOW FOR MASS SPECTROMETRY

      
Application Number 18337020
Status Pending
Filing Date 2023-06-18
First Publication Date 2023-10-19
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Hoffmann, Thomas
  • Kupser, Peter
  • Leinenbach, Andreas
  • Mitra, Indranil
  • Nandania, Jatin
  • Werner, Cornelia

Abstract

The present invention relates to a method for detecting and/or quantifying an analyte in a sample using mass spectrometry. The method of the invention comprises: extracting the analyte from the sample using solid phase extraction (SPE) so as to obtain an SPE extract comprising the analyte, concentrating the analyte, said concentrating comprising evaporating solvent from the SPE-extract; and detecting and/or quantifying the analyte in the sample using mass spectrometry.

IPC Classes  ?

68.

LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS

      
Application Number 18337018
Status Pending
Filing Date 2023-06-18
First Publication Date 2023-10-19
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Fraefel, Marius
  • Grimm, Stefanie
  • Hoffmann, Thomas

Abstract

The present invention relates to a method for detecting and/or quantifying one or more steroids using mass spectrometry, said steroids comprising at least one 11-oxygenated steroids. The method of the invention comprises (i) extracting the one or more steroids from the sample using solid phase extraction (SPE) so as to obtain an SPE extract comprising the one or more steroids; (ii) concentrating the one or more steroids, said concentrating comprising evaporating solvent from the SPE-extract; and (iii) detecting or quantifying the one or more steroids in the sample using mass spectrometry.

IPC Classes  ?

  • G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones
  • G01N 30/72 - Mass spectrometers

69.

METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE

      
Application Number 18339799
Status Pending
Filing Date 2023-06-22
First Publication Date 2023-10-19
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Fomin, Maksim
  • Heindl, Dieter
  • Hillringhaus, Lars
  • Kuchelmeister, Hannes
  • Mohamed, Mohamed Yosry Hassan
  • Oelschlaegel, Tobias
  • Simonyiova, Sona

Abstract

The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a kit, a complex, a method to synthesize a complex and the use thereof for detecting the analyte of interest in the sample.

IPC Classes  ?

  • G01N 33/533 - Production of labelled immunochemicals with fluorescent label
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • C07F 15/02 - Iron compounds

70.

REAGENT FOR MASS SPECTROMETRY

      
Application Number 17990903
Status Pending
Filing Date 2022-11-21
First Publication Date 2023-10-12
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Heindl, Dieter
  • Kobold, Uwe
  • Kuchelmeister, Hannes
  • Maerz, Heribert
  • Prencipe, Giuseppe
  • Rempt, Martin

Abstract

The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.

IPC Classes  ?

  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

71.

METHOD FOR OPTIMIZING A PARAMETER SETTING OF AT LEAST ONE MASS SPECTROMETRY DEVICE

      
Application Number 18333174
Status Pending
Filing Date 2023-06-12
First Publication Date 2023-10-12
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Tiemann, Benjamin
  • Intelmann, Daniel

Abstract

A method for optimizing at least one parameter setting of at least one mass spectrometry device (110) operating at unit resolution is disclosed. The method comprises the following steps: a) determining at least one analyte detection window for detecting an analyte of interest with the mass spectrometry device (110), wherein the analyte detection window is defined by a central mass to charge ratio value of the analyte and a predefined width, wherein the central mass to charge ratio value of the analyte is set to a theoretical mass to charge ratio value of the analyte of interest having more than one decimal place and/or a mass to charge ratio value of the analyte of interest determined by a high resolution mass spectrometry measurement having more than one decimal place; b) determining at least one internal standard detection window for detecting an internal standard substance with the mass spectrometry device (110), wherein the internal standard detection window is defined by a central mass to charge ratio value of the internal standard substance and the pre-defined width, wherein the central mass to charge ratio value of the internal standard substance is set to a mass to charge ratio value of the internal standard substance calculated relative to the analyte of interest and having more than one decimal place and/or to a mass to charge ratio value of the internal standard substance determined by a high resolution mass spectrometry measurement having more than one decimal place.

IPC Classes  ?

  • H01J 49/00 - Particle spectrometers or separator tubes
  • H01J 49/06 - Electron- or ion-optical arrangements

72.

REACTION VESSEL

      
Application Number 18335608
Status Pending
Filing Date 2023-06-15
First Publication Date 2023-10-12
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Faigle, Christoph
  • Heinemeyer, Thomas
  • Schweinberger, Florian
  • Thiele, Roland

Abstract

A reaction vessel for a diagnostic analyzer comprising a plurality of processing stations. The reaction vessel comprises at least one sensor configured to measure at least one physical parameter associated with at least one of the processing stations of the diagnostic analyzer when disposed at the at least one of the processing stations, a memory configured to at least temporarily store at least one measurement value indicating the physical parameter provided by the sensor, a processing unit configured to control the sensor and to output measurement data including the measurement value from the memory, an interface configured to provide communication of the processing unit with an external electronic device, a power source configured to supply electric power to the sensor, the processing unit and the memory. The reaction vessel defines an internal volume. The sensor, the processing unit, the memory and the interface are arranged within the internal volume.

IPC Classes  ?

  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

73.

REAGENT CONTAINER CAP, REAGENT CONTAINER UNIT AND REAGENT KIT

      
Application Number 18042786
Status Pending
Filing Date 2021-08-20
First Publication Date 2023-10-12
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Kramny, Detlev
  • Hoefflin, Klaus
  • Schulze, Antje
  • Weymann, Alex

Abstract

A Reagent container cap (116) is adapted to being mounted to a reagent container and to being adjustable, at least after an initial opening of the cap (116), between an opened state and a closed state, wherein the reagent container cap (116) defines a cap interior space (109) and has a cap opening (116o) allowing access to the cap interior space (109) from above when the cap (116) is in the opened state; and wherein, in the closed state of the cap (116), the cap interior space (109) is open only towards a bottom side (116b), wherein the reagent container cap (116) comprises a main portion (116m) and an insert portion (116i) that are fixedly connected to each other and made from different materials, wherein, when the cap (116) is in the closed state, the cap interior space (109) comprises a region (109t) which is delimited circumferentially and towards the upper side of this region completely and exclusively by surfaces of the insert portion (116i).

IPC Classes  ?

  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

74.

METHODS FOR MANAGEMENT OF PROSTATE CANCER BASED ON PSA GLYCOSYLATION

      
Application Number EP2023059129
Publication Number 2023/194529
Status In Force
Filing Date 2023-04-06
Publication Date 2023-10-12
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Cobbaert, Christa
  • Kroeniger, Konstantin
  • Lageveen-Kammeijer, Guinevere
  • Nouta, Jan
  • Rolny, Vinzent
  • Ruhaak, Renee
  • Swiatek-De Lange, Magdalena
  • Tabares, Gloria
  • Van Der Burgt, Yuri
  • Wuhrer, Manfred

Abstract

The present invention relates to methods for assessing whether or not a patient has aggressive prostate cancer by determining the levels of particular glycoforms attached to prostate specific antigen (PSA) protein in a biofluid sample of a subject, and comparing the determined level or concentration to a reference. The methods are particularly useful for assessing subjects that have 2-10 ng/ml total PSA in the subject's serum.

IPC Classes  ?

  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

75.

METHOD FOR SENSOR CALIBRATION

      
Application Number 18171469
Status Pending
Filing Date 2023-02-20
First Publication Date 2023-10-05
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Thomas, Martin

Abstract

An automated method of calibrating a sensor located in a flow-through sensor path and requiring at least one oxygenated calibration fluid for calibration comprises transporting a predefined amount of deoxygenated calibration fluid from a fluid supply into a fluidic line between a fluid-selection valve and the sensor path, transporting ambient air into the fluidic line before and after transporting the calibration fluid forming an isolated plug of calibration fluid between zones of ambient air, oscillating the calibration fluid plug back and forth within a predefined length of the fluidic line causing reciprocating fluid film tailing along the inner walls of the fluidic line, and facilitating oxygenation of the calibration fluid via oxygen uptake by the fluid film from the ambient air in the fluidic line, and transporting the oxygenated calibration fluid into the sensor path at a position where the sensor is located and calibrating the sensor.

IPC Classes  ?

  • A61B 5/1495 - Calibrating or testing in vivo probes
  • A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value

76.

DETECTION OF AN ANALYTE OF INTEREST BY CROSS SPRAY ESI MASS SPECTROMETRY

      
Application Number 18328104
Status Pending
Filing Date 2023-06-02
First Publication Date 2023-10-05
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Karaca, Samir
  • Pirkl, Nicole
  • Rempt, Martin

Abstract

The present invention relates to a method, a diagnostic system, a dopand and the use thereof for the enhancement of detection of an analyte of interest by Cross Spray ESI mass spectrometry.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • H01J 49/16 - Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission

77.

IGFBP7 FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE

      
Application Number 18021085
Status Pending
Filing Date 2021-08-12
First Publication Date 2023-10-05
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Kastner, Peter
  • Rolny, Vinzent
  • Wienhues-Thelen, Ursula-Henrike
  • Ziegler, Andre
  • Conen, David
  • Osswald, Stefan
  • Kuehne, Michael

Abstract

The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of IGFBP7 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

78.

TIMP1 AS A MARKER FOR CHOLANGIOCARCINOMA

      
Application Number 18309985
Status Pending
Filing Date 2023-05-01
First Publication Date 2023-09-28
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Dayyani, Farshid
  • Mang, Anika
  • Morgenstern, David
  • Rolny, Vinzent
  • Swiatek-De Lange, Magdalena

Abstract

The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.

IPC Classes  ?

  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

79.

SENSOR ASSEMBLY

      
Application Number 18326379
Status Pending
Filing Date 2023-05-31
First Publication Date 2023-09-28
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Lutz, Sascha
  • Ocvirk, Gregor
  • Boehm, Christoph
  • Burkhardt, Wolfgang
  • Ruf, Miriam
  • Kontschieder, Heinz

Abstract

The present disclosure refers to a sensor assembly for an IVD analyzer, the sensor comprising two opposite substrates with at least one fluidic conduit for receiving a sample. The electrodes of different types of electrochemical sensors are arranged on the two opposite substrates facing the at least one fluidic conduit for coming in contact with the sample and determining sample parameters, wherein the counter electrodes and the reference electrodes are formed on one substrate and the working electrodes are formed on the opposite substrate. This achieves optimal sensor-working conditions in terms of a homogeneous and symmetrical electric field density and enables a sensor assembly with simpler geometry and smaller size.

IPC Classes  ?

  • G01N 27/06 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a liquid
  • G01N 33/487 - Physical analysis of biological material of liquid biological material

80.

MULTIMARKER PANEL FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE

      
Application Number 18021021
Status Pending
Filing Date 2021-08-12
First Publication Date 2023-09-21
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Kastner, Peter
  • Rolny, Vinzent
  • Wienhues-Thelen, Ursula-Henrike
  • Ziegler, Andre
  • Conen, David
  • Kuehne, Michael
  • Osswald, Stefan

Abstract

The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amounts of the biomarkers Osteopontin, cardiac Troponin, a natriuretic peptide and FABP-3 in a sample from the subject, b) comparing the amounts determined in step a) to references, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

81.

TROPONIN MARKER COMBINATIONS FOR EARLY DISCRIMINATION OF TYPE 2 VERSUS TYPE 1 ACUTE MYOCARDIAL INFARCTION

      
Application Number EP2023056906
Publication Number 2023/175152
Status In Force
Filing Date 2023-03-17
Publication Date 2023-09-21
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Buehlmann, David
  • Eberl, Magdalena
  • Kastner, Peter
  • Piehler, Alexander
  • Wienhues-Thelen, Ursula-Henrike
  • Ziegler, Andre

Abstract

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

82.

CMYBPC MARKER COMBINATIONS FOR EARLY DISCRIMINATION OF TYPE 2 VERSUS TYPE 1 ACUTE MYOCARDIAL INFARCTION

      
Application Number EP2023056954
Publication Number 2023/175176
Status In Force
Filing Date 2023-03-17
Publication Date 2023-09-21
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Buehlmann, David
  • Duefel, Hartmut
  • Eberl, Magdalena
  • Gerg, Michael
  • Kastner, Peter
  • Kurtkaya, Ulrike
  • Piehler, Alexander
  • Wienhues-Thelen, Ursula-Henrike
  • Ziegler, Andre

Abstract

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being cMyBPC, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10- type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide (Brain natriuretic peptide type peptide), GDF-15 (Growth differentiation factor 15), ANG2 (Angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1), or a lipid biomarker, such as Cholesterol, LDL (Low Density Lipoprotein) or APOAT (Apolipoprotein A-1) comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being cMyBPC and a second biomarker selected from the group consisting of: a BMP10-type peptide, FGF23, a BNP-type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1, or a lipid biomarker, such as Cholesterol or LDL, or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol

83.

INTELLIGENT USER GUIDANCE FOR LABORATORY ISSUE RESOLUTION

      
Application Number 18178595
Status Pending
Filing Date 2023-03-06
First Publication Date 2023-09-14
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Hofstetter, Hermann
  • Morcillo Montejo, Alejandro

Abstract

A computer-implemented method of providing user guidance for laboratory issue resolution within a laboratory system is presented. The method comprises monitoring activity by a user within a laboratory setting of the laboratory system by a user guidance system, detecting a laboratory issue within the laboratory system, retrieving by the user guidance system a preferred resolution to the detected laboratory issue and typical time to perform preferred solution from a database, notifying the user to the laboratory issue, detecting a non-preferred issue resolution for the laboratory issue being performed by the user, displaying the user guidance system to the user, wherein the user guidance system provides the retrieved preferred resolution for the laboratory issue to the user, resolving the laboratory issue by the user using the user guidance system, and removing or updating the display of the user guidance system following the resolution of the laboratory issue.

IPC Classes  ?

  • G06Q 10/0631 - Resource planning, allocation, distributing or scheduling for enterprises or organisations
  • G06Q 10/0639 - Performance analysis of employees; Performance analysis of enterprise or organisation operations

84.

AUTOMATED ANALYSIS DEVICE

      
Application Number JP2023002996
Publication Number 2023/162591
Status In Force
Filing Date 2023-01-31
Publication Date 2023-08-31
Owner
  • HITACHI HIGH-TECH CORPORATION (Japan)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Tsushima Yuki
  • Usui Takafumi
  • Aschenbrenner Daniel
  • Boehm Julia
  • Hinz Daniela
  • Steigenberger Maximilian

Abstract

The present invention includes: a reagent vessel holding part that holds a reagent vessel for accommodating a reagent; a reagent vessel information detection unit that detects information relating to the reagent vessel; a display unit that displays a screen including an operation region where operations from a user are received; and a control unit that causes the display unit to display the screen. The control unit has: a vessel presence/absence determination unit that determines whether the reagent vessel is present in the reagent vessel holding unit on the basis of the information detected by the reagent vessel information detection unit; a first operation region output unit that outputs, to the screen, a first operation region which is operated when the user has confirmed removal of the reagent vessel; a second operation region output unit that outputs, to the screen, a second operation region which is operated when shutdown is performed; and a warning output unit that outputs, to the screen, a warning prompting removal of the reagent vessel when the vessel presence/absence determination unit has determined that the reagent vessel is present. The foregoing makes it possible to provide an automated analysis device which prevents shutdown from starting while a reagent has been left behind.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

85.

METHOD AND DEVICES FOR POINT-OF-CARE APPLICATIONS

      
Application Number 18311631
Status Pending
Filing Date 2023-05-03
First Publication Date 2023-08-31
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Maier, Michael
  • Porsch, Ulrich
  • Schmitz, Ralf

Abstract

A handheld diagnostic device, specifically for point-of-care applications. The handheld diagnostic device comprises at least one diagnostic measurement unit configured for performing at least one diagnostic measurement, the diagnostic measurement unit comprising at least one test element port for determining at least one diagnostic parameter of at least one patient by using at least one diagnostic test element; at least one camera configured for capturing at least one image of at least one wound of the patient; and at least one control unit, the control unit being configured for controlling the diagnostic measurement and for controlling the capturing of the image of the wound, wherein the control unit is further configured for storing at least one measurement result of the diagnostic measurement and the at least one image in at least one database record of the patient. A diagnostic system and a diagnostic method are further disclosed.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
  • A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition

86.

DERIVATIZATION OF AT LEAST ONE ANALYTE OF INTEREST FOR MASS SPEC MEASUREMENTS IN PATIENT SAMPLES

      
Application Number 18312442
Status Pending
Filing Date 2023-05-04
First Publication Date 2023-08-31
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Arnhard, Kathrin
  • Clemens, Christian
  • Vondenhoff, Gaston Hubertus Maria

Abstract

The present invention relates to a method for determining the presence or level of an analyte of interest and the use thereof. Further, present invention relates to an analytical system, a sampling tube and the use of the sampling tube and a nucleophilic derivatization reagent.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N 33/94 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics
  • G01N 30/72 - Mass spectrometers

87.

Component of a holder and storage device for reagent tubes

      
Application Number 29771377
Grant Number D0997382
Status In Force
Filing Date 2021-02-22
First Publication Date 2023-08-29
Grant Date 2023-08-29
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Weymann, Alex
  • Kramny, Detlev

88.

METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST

      
Application Number 18107996
Status Pending
Filing Date 2023-02-09
First Publication Date 2023-08-24
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Heindl, Dieter
  • Rempt, Martin
  • Seitz, Manuel Josef
  • Zuth, Christoph

Abstract

The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a sample element, a device, a kit and the use thereof for determining at least one analyte of interest.

IPC Classes  ?

  • G01N 30/72 - Mass spectrometers
  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

89.

METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE

      
Application Number EP2023053868
Publication Number 2023/156510
Status In Force
Filing Date 2023-02-16
Publication Date 2023-08-24
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Agrawalla, Bikram Keshari
  • Ansideri, Francesco
  • Heindl, Dieter
  • Hillringhaus, Lars
  • Kuchelmeister, Hannes
  • Prencipe, Giuseppe
  • Simonyiova, Sona

Abstract

The present invention relates to a method for determining at least one analyte of interest and the use thereof. The present invention further relates to a kit, a complex, a method to synthesize a complex, a monomer and the use thereof for detecting the analyte of interest in the sample.

IPC Classes  ?

  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

90.

DLL1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS

      
Application Number EP2023054199
Publication Number 2023/156655
Status In Force
Filing Date 2023-02-20
Publication Date 2023-08-24
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Gruenewald, Felix
  • Heinz, Kathrin
  • Klammer, Martin
  • Plaszczyca, Anna Maria
  • Schuetz, Philipp
  • Von Holtey, Maria
  • Weber, Stephen

Abstract

The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being DLL1, determining the amount of a second biomarker in a sample of the subject, said second biomarker being GDF15, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being DLL1 and a second biomarker being GDF15, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

91.

METHOD FOR IMPROVING CROSS-FLOW FILTRATION AND CROSS-FLOW FILTRATION SYSTEM

      
Application Number EP2023054272
Publication Number 2023/156672
Status In Force
Filing Date 2023-02-21
Publication Date 2023-08-24
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Munoz, Carlos
  • Zahn, Hans

Abstract

A method of cross-flow filtering wastewater from a diagnostic apparatus or a laboratory analyser, wherein the wastewater comprises nanoparticles and/or microparticles, and the wastewater is streaming in a laminar flow across a surface of a filter membrane, the method comprising: (a) streaming the wastewater across the surface of the filter membrane with a flow rate, so that the flow of the wastewater is a laminar flow with a Reynolds number (Re) of smaller than 500; (b) streaming the wastewater in pulse cycles across the surface of the filter membrane, wherein each pulse cycle comprises one active phase in which the wastewater is under a duty pressure and one inactive phase in which the wastewater is under an inactive pressure, wherein the inactive pressure is no more than 10% of the duty pressure and the active phases have a duration of greater than 50 % of the corresponding pulse cycles; and (c) separating the nanoparticles and/or microparticles from the wastewater when the wastewater passes through the filter membrane. Also described is a cross-flow filtration system configured for performing the method.

IPC Classes  ?

  • B01D 61/12 - Controlling or regulating
  • B01D 61/22 - Controlling or regulating
  • B01D 65/08 - Prevention of membrane fouling or of concentration polarisation
  • C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

92.

LABORATORY SYSTEM

      
Application Number 18168679
Status Pending
Filing Date 2023-02-14
First Publication Date 2023-08-17
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Kollmer, Markus
  • Mahmoud, Yanis Ali
  • Rein, Michael
  • Vasile, Teodor Laurentiu

Abstract

A laboratory system, comprising: at least one rack comprising retainers, wherein the rack is adapted to carry laboratory sample containers inserted in the retainers, a handling device, wherein the handling device is adapted to insert sample containers in the retainers or remove containers from the retainers being placed at a processing position depending on location information indicating the location of the rack being placed at the processing position relative to the handling device, a plurality of teaching devices, wherein a respective teaching device is insertable into a retainer of the rack, and wherein at least two teaching devices are inserted into a corresponding retainer of the rack being placed at the processing position, and a location information calculating device, wherein the calculating device is adapted to calculate the location information of the rack being placed at the processing position depending on the location of the at least two teaching devices.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

93.

MONITORING DEVICE FOR MONITORING AN ELECTRIC MOTOR IN A LABORATORY SYSTEM

      
Application Number 18308847
Status Pending
Filing Date 2023-04-28
First Publication Date 2023-08-17
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor Berberich, Walter

Abstract

A monitoring device for monitoring an electric motor, specifically of a laboratory system, is disclosed. The monitoring device comprises at least one receiving unit configured for receiving information on at least one amount of acceleration energy required for accelerating the electric motor from at least one first motion state to at least one second motion state and at least one evaluation unit configured for evaluating the information on the amount of acceleration energy and for determining at least one item of information on a wearing status of the electric motor. The acceleration energy comprises an acceleration energy which is at least one of dissipated, recuperated or released when decelerating the electric motor from a rotating motion state to a stationary state. Further, a laboratory system, a method of monitoring an electric motor, a method of operating a laboratory system, computer programs and computer-readable storage media are disclosed.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G01R 31/34 - Testing dynamo-electric machines

94.

COMPONENT ABNORMALITY DETECTING SYSTEM, AUTOMATED ANALYZING DEVICE, AND COMPONENT ABNORMALITY DETECTING METHOD

      
Application Number JP2022046035
Publication Number 2023/153073
Status In Force
Filing Date 2022-12-14
Publication Date 2023-08-17
Owner
  • HITACHI HIGH-TECH CORPORATION (Japan)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Sasaki Shunsuke
  • Imai Kenta
  • Hadorn Maik Roger
  • Kuehnl Michael
  • Pukas Darius
  • Brzezinski Mikolaj
  • Marchewa Janusz

Abstract

Provided is a component abnormality detecting system for detecting an abnormality of a component of a liquid transport system that sucks in and discharges a liquid to and from a sample inspection sensor of an automated analyzing device, the component abnormality detecting system comprising a storage device for storing data of an electrical signal output by the sensor, and a processing device for processing the data recorded in the storage device, wherein the processing device detects an abnormality of a component of the liquid transport system on the basis of the electrical signal.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G01N 35/08 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis

95.

SYSTEMS AND METHODS FOR STAINING OF BIOLOGICAL SAMPLES

      
Application Number 18137254
Status Pending
Filing Date 2023-04-20
First Publication Date 2023-08-17
Owner
  • Ventana Medical Systems, Inc. (USA)
  • Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Drechsler, Andreas
  • Gutmann, Oliver
  • Hazar, Melis
  • Huesser, Reto
  • Kozikowski, Iii, Raymond T.
  • Mueller, Daniel
  • Steinert, Chris

Abstract

A system and method for treatment of biological samples is disclosed. In some embodiments, an automated biological sample staining system (100), comprising at least one microfluidic reagent applicator (118); at least one bulk fluid applicator (116); at least one fluid aspirator; at least one sample substrate holder; at least one relative motion system; and a control system (102) that is programmed to execute at least one staining protocol on a sample mounted on a substrate that is held in the at least one sample substrate holder.

IPC Classes  ?

  • G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
  • G01N 1/31 - Apparatus therefor

96.

METHOD FOR DETERMINING THE LEVEL OF VITAMIN D AND METABOLITES THEREOF

      
Application Number 18125708
Status Pending
Filing Date 2023-03-23
First Publication Date 2023-08-10
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Baecher, Silvia
  • Geistanger, Andrea
  • Gruber, Dominik
  • Josel, Hans-Peter

Abstract

The present invention relates to a method and the use thereof for for determining the level of Vitamin D and metabolites thereof. Further, it is an object of the present invention to provide a kit and the use thereof for determining the level of Vitamin D and metabolites thereof.

IPC Classes  ?

  • G01N 33/82 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins

97.

COMPUTER-IMPLEMENTED METHOD FOR DETECTING AT LEAST ONE INTERFERENCE AND/OR AT LEAST ONE ARTEFACT IN AT LEAST ONE CHROMATOGRAM

      
Application Number 18124837
Status Pending
Filing Date 2023-03-22
First Publication Date 2023-08-10
Owner Roche Diagnostics Operations, Inc. (USA)
Inventor
  • Michely, Julian
  • Reichert, Andreas

Abstract

A computer-implemented method for detecting at least one interference and/or at least one artefact in at least one chromatogram determined by at least one mass spectrometry device (110) is proposed. The chromatogram comprises a plurality of raw data points. The method comprises the following steps: a) retrieving the at least one chromatogram by at least one processing device (126); b) applying at least one peak fit modelling to the chromatogram by using the processing device (126); c) determining information about residuals of the raw data points by using the processing device (126); d) detecting the at least one interference and/or the at least one artefact by using the processing device (126) by comparing the determined information about the residuals with at least one pre-determined threshold, wherein, if the determined information about the residuals exceed the pre-determined threshold, the at least one interference and/or the at least one artefact is detected.

IPC Classes  ?

98.

ELECTROCHEMILUMINESCENCE METHOD OF DETECTING AN ANALYTE IN A LIQUID SAMPLE AND ANALYSIS SYSTEM

      
Application Number 18300689
Status Pending
Filing Date 2023-04-14
First Publication Date 2023-08-10
Owner
  • Roche Diagnostics Operations, Inc. (USA)
  • Hitachi High-Tech Corporation (Japan)
Inventor
  • Kraus, Ralf
  • Larbolette, Oliver
  • Staebler, Friedrich
  • Yamashita, Yoshihiro
  • Sakashita, Yukinori
  • Matsuoka, Shinya
  • Saito, Michihiro
  • Sakazume, Taku
  • Takahashi, Katsuaki

Abstract

An electrochemiluminescence method of detecting an analyte in a liquid sample and a corresponding analysis system. An analyte in a liquid sample is detected by first providing a receptacle containing a fluid comprising protein coated magnetic microparticles to a stirring unit. Stirring of the fluid is necessary since the density of the microparticles is usually higher than the density of the buffer fluid. Thus the microparticles tend to deposit on the bottom of the receptacle leading to an aggregation of the microparticles because of weak interactions. To obtain representative measurements a homogeneous distribution of the microparticles in the buffer fluid is necessary to ensure a constant concentration of microparticles for each analysis cycle. It is further necessary to provide disaggregation of the microparticles, which is also realized by stirring the fluid. Stirring is conducted with a rotational frequency that is adapted to the amount of fluid to be stirred.

IPC Classes  ?

  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N 21/66 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
  • G01N 21/76 - Chemiluminescence; Bioluminescence
  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G01N 21/69 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence specially adapted for fluids

99.

DETERMINING LIKELIHOOD OF KIDNEY FAILURE

      
Application Number EP2023051707
Publication Number 2023/144154
Status In Force
Filing Date 2023-01-24
Publication Date 2023-08-03
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Danzer, Carsten
  • Emons, Martin Josef
  • Klammer, Martin
  • Sillitoe, Nicolas Seungoon
  • Triunfo, Riccardo

Abstract

pRR0000p0000p0iiiii, a statistical parameter derived from a linear regression of the plurality of past eGFR values; and applying a machine-learning model to the input data to generate an output indicating the likelihood of kidney failure within the given amount of time Δt. Corresponding training methods and systems are also provided.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

100.

METHOD FOR OPERATING LABORATORY SYSTEM AND LABORATORY SYSTEM

      
Application Number EP2022087031
Publication Number 2023/138863
Status In Force
Filing Date 2022-12-20
Publication Date 2023-07-27
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
Inventor
  • Lambaek, Ole
  • Taeymans, Bert
  • Schnarwiler, Dominik

Abstract

A method for operating a laboratory system is disclosed, comprising providing a laboratory system having a plurality of sample containers (1) configured to contain a sample to be processed for at least one of pre-analysis and analysis in the laboratory system; a plurality of laboratory devices (2; 3; 4; 6) providing for a plurality of target devices each configured to handle one or more sample containers from the plurality of sample containers (1), the one or more sample containers being assigned for handling to the target device in operation of the laboratory system; and a control device (5) configured to at least control assignment of the plurality of sample containers (1) to the plurality of target devices; and assigning the plurality of sample containers (1) to the plurality of target devices in operation of the laboratory system. The assigning comprises: determining a target device workload state for each of the plurality of target devices, the target device workload state being in a range between a first range limit indicative of a first capacity for handling sample containers and a second range limit indicative a second capacity for handling sample containers, the second capacity being a higher capacity than the first capacity for handling sample containers, and determined according to a metric being proportional to a resource target device state indicative of a present number of sample containers assigned to the target device, and a power of an output flow of the target device, the output flow being indicative of output of sample containers per time by the target device; assigning the plurality of sample containers (1) to the plurality of target devices according to the target device workload states; and providing the plurality of sample containers (1) to the plurality of target devices for handling according to the assignment. Furthermore, a laboratory system is provided.

IPC Classes  ?

  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G05B 19/042 - Programme control other than numerical control, i.e. in sequence controllers or logic controllers using digital processors
  • G05B 19/418 - Total factory control, i.e. centrally controlling a plurality of machines, e.g. direct or distributed numerical control (DNC), flexible manufacturing systems (FMS), integrated manufacturing systems (IMS), computer integrated manufacturing (CIM)
  • G06Q 50/22 - Social work
  • G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
  1     2     3     ...     14        Next Page